


Regeneration and Repair in Cardiovascular Disease, Obstacles and Opportunities

Miguel G Garber
 Revitacell Clinic, Spain

The primary cause of death among chronic diseases worldwide is ischemic cardiovascular diseases, such as stroke and myocardial infarction. Recent evidence indicates that adult Mesenchymal stem cells therapy aimed at restoring organ function, and cardiovascular repair represent promising strategies to treat cardiovascular diseases, and have been recognized as one of the potential therapeutic agents, following several tests in animal models and clinical trials. In the process, various sources of mesenchymal stem cells have been identified which help in cardiac regeneration by either revitalizing the cardiac stem cells or revascularizing the heart. Although mesenchymal cell therapy has achieved considerable admiration and promising therapeutic strategy is the priming of therapeutic MSCs with stem cell modulators before transplantation therapeutic efficacy of MSCs *In vitro* or *In vivo* from cell priming to tissue engineering strategies, for use some challenges still remain that need to be overcome in order to establish it as a successful technique, questions going on: Which specific types of stem cells are likely to be most effective? Can heart cells divide, and if so, can we develop strategies to stimulate the growth and differentiation of the cardiac cells left in the injured heart to promote recovery of tissue mass and function?

Nobody knows at the time being what will be the best therapy for our patients. “We may need different cells for different patients and different cells for drug discovery or tissue engineering.” Which cell(s) will ultimately prove to be useful in patients is a matter of opinion.



Biography:

Dr. Miguel G. Garber has over 32 years of experience in Internal Medicine and Cardiology, in addition to training, research, and development expertise in Regenerative Medicine. Over the past 12 years, he has made a significant contribution to stem cell research, specializing in the exploration and development of stem cell therapies for cardiac disorders, osteoarthritis, and neurological and autoimmune diseases. Formerly the Director of American Medical Information Group, he now serves as the Medical Director of Regenerative Medicine Madrid and the President of the Spanish Society of Regenerative Medicine and Cell Therapy (SEMERETEC). He also teaches a Master's degree program in Regenerative Medicine and edits a number of scholarly journals on the subject.